R•gl$tered number: 07682372 Charbty number: 1171827 EUROPEAN ASSOCIATION FOR CANCER RESEARCH (A company limlted by guarantee TRUSTEES. REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 EUROPEAN ASSOCIATION FOR CANCER RESEARCH (A company Ilmlted by guarants•) Page Refèrèncè and administrative d•tail# ol thè Ch*My, its Tntst•es afbd a￿#• Trust••s' r•port Inde￿ndent audltors. report ¢)n th• slal•m Stat•mont of flnanclal actlvlll•s 7-10 11 Balanu sh•et 12 Ststsment of cash flows 13 Noles to ffinan¢lal statsmonts 14-31 EUROPEAN ASSOCIATION FOR CANCER RESEARCH (A company limiled by guarantso) REFERENCE P>4D ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 DECEMBER 2023 TrustB•S C. A. Baidelli R. Bemards H. M. F. Bla￿lin De Tr C. Caklas C. Dive N. Erez E. Liarud N. Lopez &gas E. Oiicchio Y. R. Swnuels J. Seoane liewd 19 June 2023) A. Twmpp J. K. Weslem)arck Company r•glster•d numbèr 07682372 Charlty roghtsred numb•r 1171827 RBgistored office &r Cdin CampWI Universty of Nottingham IrxK>valiM Park Triumph Road Noth"ngham NG7 2TU Company 8Kr•lary J Smilh Ind8pond•nt auditorn PKF Smith Co¢w Audit Limi Stslutory Audit￿5 2 Lace Mathet Square Nottingham NG1 1PB Sonlor managem•nt leam J Smith, c￿et Exe(xthe Offiw (CEO) Page 1 EUROPEAN ASSOCIATION FOR CANCER RESEARCH (A company limltsd by gu¥ant••l TRUSTEES. REPORT FOR THE YEAR ENDED 31 DECEMBER 2023 The Trustees {who are also dtytttors of the chanty f¢X the wrposes of the Companies Acti wesent their annual report logetheT Wth the audited financial statements of the European Association for Cancer Research IUCRI Ilhe Charty) for the 1 January 2023 10 31 De¢ember 2023. The Annu* repcrt s¢￿e$ the purp¢)ses of both a Trustees. report and a directors, rewt ￿KleT company I￿. Th8 Trustees confirm that the Annual report and finan¢i* stslemenl$ ot the Charty comF4y with the currerrt statutory requirements, Ihe requirement5 Of the Charitys governing document and the P￿S￿5 of ts Statemenl of Recommended Practice ISORP) applicable to chwties preparing Iher accounts in xc(Xd￿¢e ¥￿th the FIn￿CIal Reporting SlaThJard applKatr4e in the UK and Republic of Ireland (FRS102) (effective 1 January 20191. Since the Charity qualffies as small WKler Secti￿ 382 of the comp￿$ Aci 2006. the Strategic report required of medium and companie$ Lndw tr* Acl 2006 Istratew Report aid Th"Teciors' Report) Regl￿allonS 2013 has been c*nitted. Oblectlv•s and a¢tlv#le• a. Pollclm and obl•ctlv The object of the AssocIa￿n is the thanc￿￿￿ of caxer research. fty the ptknlic benefit. from basic research to prevention treatment and care. b. Strat•gl•s for a¢hhving obJ•ctiv• The EACR aims to ￿leVe its Missi￿ by. Fostering collaboralion betr￿￿ its members Faalitating interaction tse￿n its members WKI Ihe wder cancer research COMM￿lty HigNighling. COMML￿1Catrng and celebfating the work of its memb Educating. developing and supporling cwcer scients'sls al all $tsges of thew carws c. kllvllle$ undgrtakgn lo a¢hkn obJ•clAves The EACR supports its members to make prcgr8ss in researching new ways to wevenl, detect and Ireal cancer by prowding education. infcKmalion. ne￿￿rki￿ and funding opportwities. 11 also provides infomalion lo the public via a free email bLdlekn'n and throu￿1 its web&te. thgtal magazine. and podcast. By 5UPPOrtng cancer researcher5 in this way. the Assooyation achieve its purFM)se of making progress in the fight against t￿r. for the ber￿rt ofthe wblic. d. Pd>llc b•nefit In setting obiecti'ves aThJ pl￿ning activi￿. the TTUStees have uiven due c￿nSIderation to general guTrdance pthli5hed by the Charty Commissicffi relatiThJ to benefL In particular. the Trustee5 consider how planned activits￿ will c¢￿tribUte lo WKI they have seL The object of the EACR is the aifvarKemenl of Ca￿ research. for the p￿liC benefft. from basic research lo Pfevention I￿ats￿ent aTrJ care. TrNS is acf¥eved by weasiThJ the knowledge of researchers professionals and fostering greater collaborab.cffi amongst those wothing n the carter fields, with a lo inefeaslng ¢aneer sumyal rates and improving treatments patths. The Association provides a wide variety of ser¥xes to its ccrfnmunty of members, organises scientific m￿lIngS and events. and facilitsles ￿mmuniCatiOn and coliaboratiw. It ajso sets ¢yJt to champion the importance of ￿￿ling for curiosity-driven saenliffic research. Page 2 EUROPEAN ASSOCIATION FOR CANCER RESEARCH (A c(xnpany limit•d by guarant•el TRUSTEES. REPORT ICONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Achlwements and p•rfornian . R•vl•w of actlvilios During 2023, the Board developed its new straleg￿ pl￿ 202*2028. to replace the Shorter temis plan that was in place lo steer the organisalion lfv￿gh immedi*e post-pan(lemic PWk)d. The Board continued to seek advice from ils Advisory Council on strategic matters., the Counal met in January 2023 and considered. inter alia, the EACR'S industy r81ationships Wblh industy and htr4rf the orwisation mi￿( Sup[￿ mid.career and s¢nior researchers. In October 2022. the Board •JTeed lo eslaNish an Éarty C￿e8r Rese¥c*￿￿ Counul to consider and proposes to the Board new ways in ￿1c￿ the EACR can supFort arnl develop re$epAcher$ in the early stages of their careers. Eight twr￿ing members were nominated by the Board Iho Council hèld its first meeting in January 2023. Over th8 ￿ar, the Council has gone from strength to strength and has held virtual netsyorking sessions. as well as plannirvj an irFperson syynpowm to take place at the congre55 in June 2024. EACR staffing was stable in 2023, Confer8nc8 Oknr joining in February 2023 and no changes since. A successlul akstsff away day was hekl li ￿Y 2023 and the leam continues to grcw arNI devekjp. The EACR was able lo continue retum lo in-person Confe￿nceS in 2023. vthilst ￿ntInuing to delivw some conferences arKI Webir￿[S online. In June 2023, a suc£essful in-person congress was h81d in Turin. Il*. This was the EACR'S largest ever event. wilh ffl(￿e than 2,000 peo* takin9 part. Fundmg opportunities lor members continwl to be expanded in 2023. The Travd Fello%￿lP scheme made 29 awards ftom 84 applications. Four I￿ldOCtoral Feknyships were avrarded.. two funded by Astra Zeneca and by Boethn9er Ingdhewn. Some of these wqects *ill start li 2024. Mambers and the publi¢ were kept Ip lo date aLXivil'es, news and events in the cancer research communty via the fortr￿ghtlY email ￿￿elIn. the EACR website and digilal magazNie, The Can¢er Re5ewcher. In March 2023. we laurKhe(I the first epi￿ of cojr nthv pothasl wheie renowned researchars from around the wort discvss their pers￿al expo￿nCeS and Ir￿￿)hts on navigating a careei in academia wlh our Suentific Officer A lotsl of 8 ekxsodes were published in 2023. arKI feedback has been oveywhelming positive. EACR member numbers grow ty 6.5% in 2022 and feedbar* frem the annual member swvey was aga￿ very positive. Membership fees were mwntsll￿d at 2022 1thl$. with a increase awd to be implgmented January 2024. b. Key managem•nt personnel remuneratlon All employed stsff ￿ appointed to r￿e$ which are matd*d to the Unr¥ersity of Noth"ngham administrative staff salary scale. Terms and corKlthons of emrAoyment 81so malch tr￿Se of the Univer$ity. refleetrng the EACR'S past assoaalion wlh the Univerwty. Thefe is an annual appraisal pr(Kess. wilh salary uplifts linked to perfomiance. The CEO'S perfcrfma￿e is reviw*ed by EX￿1Ve Ccthmiitee. Page 3 EUROPEAN ASSOCIATION FOR CANCER RESEARCH IA company limit•d by guarantoel TRUSTEES. REPORT (COKllNUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Fknanclal revlew a. Golng COn￿M After m8kirwJ ¥propriate enwiries. the trustees have a reasonable expectation that the Ch*ity has adequate resolwces lo cc4ttinue in operatiorwl e*istence for the foreseeable fulwe. For this rea￿. they continue lo adopt the going concem basis in preparing the financial slalements. Furlhgr dgtails regar(ling the adoption of the go￿9 coneem basis can te I(￿nd in the AcC￿u￿11*Yj Policies. b. pollcy At its Oct0t￿ 2022 meeb'ng. the Board reviv*ed its ffesep￿ Fx*y, in the of the increased stsff headcowt and the better than budgeted fin￿cial kYJSrti¢)n. The suggests that in the long-temi. the EACR should hold reserves bets￿en É444,000 and É729.0C￿. ReseNes are cuffenty signrfKanty higher than ltr¥s, but the Board has these should be reduced tine. The tarw reseNes range VAII be re¥ie*4ed in June 2024. along a lon9-range finarKia foreeast. c. PrI￿1paI rlsks and un¢•rtalntkns The Board eontinuèd to keep the EACR'S f￿￿￿4a1 po&iNJ) urKkn djse review in 2023. The risk register was r8vwed in janu￿ and October 2023. In January a risk associated intemab.onal banking and sancts'oned countries was added to Ihe regtSter, and in both Covhl-19 and Brexrt were removed as on-going dsks. The more general risk of a pandemidterrorist Ihreal is relained. The Board also a￿d that the risk lallhouth not the severity of impxt) of a c>b•r attxk ShO￿d be add8d to th• register. The major risk reman$ the poor p8rfomiance of ￿ arfftwl coThJress, need to canc81 a congress, as the charity relies on the ujngress for a wgnifThnt kYop(*t'cfi of its income. However. the strategy to dNersify income is redwng the reliance on this siigle event. and therefore rethK*g the rtsk over time. d. Flnanclal rlsk manag•mont The Trustees have assessed the major risks to whKh the Charity is exposed. in particular lI￿se Telaled lo the operations and finances of the Charty. arKJ *e satisfied that systems and wo￿aure$ are in place to miligale exKwuie lo the maior risks. The Risks Register is revM¥ed and updated at le8St ￿lee exh year. è. Princlpal funding The EACR receives fvTth from grants WKI donalMTh. partnerth"p agreefflenl8. membershp lees. conference attendano fee$, sponsorship and advertising. f. Fun¢trablng Th8 EACR does ￿t employ wofe53ional knthaisers. The wtlic we invited lo donate to the EACR through a link on the website lo the EACR'S JustGivin9 page. g. 2023 revlgw and doslng position The 2023 outccrfne was very ck>se to bty.. a F￿an￿￿j again51 bud￿ of £129.407 wa5 recorded. The outcome brings the thari￿s lunds to £1.839.987 Page 4 EUROPEAN ASSOCIATION FOR CANCER RESEARCH (A company limited by guarantw) TRUSTEES. REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Structuro, gov•rnanc• and manag•m•nt a. Constltutlon EACR is a ccrfnpany limited by guarantee (07682372) a r¢￿stered tharity in EThJland and Wales (1171827). b. M•thods of appointment or elecllon of Twsto0¥ The managemw* of the d)arity r8 ￿ reSp￿￿tAllty of ts 15 trust805 T*ho are elected aThJ ¢￿(pIed under Ihe 18rms of the ￿tideS of Associalion.. https'.IleaCr.cv￿gOvem￿¢e1cOns1I￿.0ft. EACR members ar8 invited to make nominati￿ for new Board munbers. N¢)minations are considered by Nominating Committee which athses the Board on rts woposa15 for the appointmenl of members of the Board. The Nom￿a￿.￿9 Committge sets out to recommerKI rKrfninees of the hwhest calitrxe for wisideralion by the Boafd and umimatdy the approval of the General Assemlty. The Bowd makes nominations I(￿ Offi￿rS. again appfoval by the General Assembly. New trustaes are pfovided wth ftll inf0m￿tIOn to brief them (*) ther legal obligatbjns urKler chanty and company law. No new Trustees were appointed in 2023. c. Organlsatlonal strn¢tur• and d•clsionrymaking polici•s The Board of Trustees, V•fvch can have belween 12 a¥J 16 members. admiiisters tho charity. The Bowd meets al least fvee times each year. 11 sets th8 strategic direCtic￿ for the ￿ganIsat￿)n, which is imF4emenled by the employed staff. through an annual operation* plan. Progress against th's operatic￿1 plan is monitored annually by the Board. along wth a review at every meeting of financial perfonnanee against budget. and updated budget forecasts. A KPI repothg dashboard was introd￿ed in 2023 is reviewed annually by the managemenl l&am and the Board. The current strategic plan 15 avalable al". https.1leacr.￿gIgoYeManc￿straIe9C-P1on. The Execuiive Commtttee. conslsling of the President. President Elect. Past Pre￿dent, Secretary General aTrJ Treasurer, has devolved authority to take dea9￿$ be1we￿ Board meeliThJs. The Committee. r4us the CEO, meets by video call onc8 every month. All deasions taken ty t￿$ cc￿Mittee are reF￿ed to the Board at the next fLffl Board meeling. Plan$ lor futur• perl¢)ds The Strategic Plan sets out the EACR'S plans for 2024-2￿28. In plan to reduce reserves over lime, the charity aims to introdLte new (￿dIng op￿rtUnitieS for ils members, lo S￿pOrt them in their research. Career development and new onlin8 nefvthing c￿￿tl￿ltieS wll continL* to be developed.. in 2024 we wll offer an opportunity lo undertake a fdlowshp in a seienlffic pumal and will provide online courses to enable some members to develop their leadèrthp and comM￿￿tion skilb5. Membetship fees wll be kept low lo enable exisling membws to malnlain ther membership and to e￿)Urage member5 tojoin. Funds hgld u custodian There are no funds hdd as atslodian. Page 5 EUROPEAN ASSOCIATION FOR CANCER RESEARCH TRUSTE&Y REPORT {CONTINUED FOR ThE YEAR EIIDED 31 DECEIABER 2023 Trustees (wFK• ¥re *so ts direCtc￿ of thè Charity purp08es of (wpany we ￿p)nSitrAo for eparino the Trustw. rep￿1 the finarfial Stateme￿ in accordance *ith applKabte lkn¥ Untsd lfjngdom ACc￿.￿j &andards {iknittid ￿ng￿rn Generaly Acceoed Accounting Pracbc•l. Company law requires the TnJstees io pre￿ fin*tt781 statemenis for each fina￿la5 . ith>Jer ecmpany l*v. Ihe Trustees must not appmve the finaKfal st*ments unless they ar• satisfied that they •vè a tnjè and lair Mew of the state of affaNs of the Charity of hs inr#xnlng re￿[Ce$ and applicafion of resources. ￿thdIng Its IrKome and exper￿$(ure. for that peric•d. In prepwwu these fin￿[al staten*nts. the TnJst8es •rn required to.. otréeM the method8 and wirKiples ofthe Chaths SORP IFRS 102).. state whether applicable UK Ac(%xmting Standwds {FRS 1021 have been foNow8d. subJ8dto any m8tert81 de￿tu￿$ di8d0S￿ ext4ain&J in jher￿artial staten￿ts. prepare lh• finarthl statements goYwJ r•rKem basis unless it ts W￿p1￿1* to wesume that Ihe Char*i conllnue in knJsw*6S. the Charity's transactions disdose ￿3$on￿lIa acarracy at anytimè thè fiftaThi•l ptssiticffi ofthe Charity d *naÈ4e them to enwjre that the financaal st*emerrts conwy with the compani￿ AGI 20Cfj. They are also spJnsitrle fof safegjardiry the ¥$sets oflhe Ch•1y￿d fc*t&kry reasonaL4e steps forthe pre¥￿tIon and delecb.on offr4ud and othw Tregularit￿. Each of the pwsons are Trusiees attr til￿ this Tn&stees' report i¥ approved ha¥ confjrmed thatr. so f* as that TnBtse i¥ *v¥e. flwe relv4ant aL**I ink¥malion of the Charitrfs auditors ar• ur￿re, and that TnFStÈ• has tsk￿ all thè ought to Iwvè bÈÈn lakèn as a Trustee tn Lwder to bè aware of Auditors The a￿litOrs. PKF Smth COOFW A￿j11 Linffi&l. ha￿ willi1w￿ to ¢ontinue in offi￿. The cprov•d by ordw ofthe Mon*)e￿ ofthe l>D*d ofTnths ¥rfl W on their b¢haWbr. R. Bernards (Chair of Trustees) rr]d) l. ?(ylL. Page6 EUROPEAN ￿8$ocIA￿oN FOR CANCER RESEARCH (A Company Ilmited by guarant•e) INDEPENDENT AUDITORS. REPORT TO THE TRUSTEES OF EUROPEAN PSSOCIATION FOR CANCER RESE)ACH Oplnlon W8 ha¥8 aLKlited the finanaal s&￿eMentS of Ewopean As$￿all￿ fcf Cwcer Researeh Ilhe 'Charityl for the year ended 31 December 2023 wlM"th comprise the Statement of financial aclivilies. Ihe Balance $heet. the Slalement of cash Ilows arKI the related note$. incluthng a S￿)Mary of signfficanl accounting policie5. The financial reporting framewotk Ihat has been applied in their preParat￿n is apph"cable law and United Kingdom Accounting Standards, including Financial Rewting Si*dard 102 'The Finanual Reporbng Standard applicablo in the UK and Repubh"c of Irel￿d. (United Kmgdom GeneraltyAccèpted AcCou￿1Th9 Practice). In our ¢)pinion the financial statements". give a true and far view of the slale of the Ch¥ity$ affair¥ as at 31 December 2023 and of its ￿comIng resources and apphcatton of resources. irKIL*Jing its Ir￿ome and eXpendrt￿e for the ￿ar then ended., have been property prepared in with United Kir￿thm Generally Accepted Accounting Practice,. aThY have been prepared in accordance ￿ the wirements of the Companies Act 20￿. Basls for oplnk We condueted our audit in acC(*dar￿e with 1rrternall￿aI S￿dards on AuditiThJ {UKI {ISAs IUKII and applicable law. Our responsibilities urKler those s￿dardS are furthor described in the Audrtors. responsibilities for the audit of the finanryal slatements sectr•n of tyjr report We are y￿ependent of th8 Charity in accordance with the ethical requirgmgnts that are rdevant to OLY audit of the finarKial statements in the United Kngdom. inchjdng the Financial Reporting Council's Ethic￿ Standard. and VR have fulfilled our olhw ethical re$Fon$ibilittes in accordance w1h these reqLMrements. We belwe that audil e¥KJerKe we have obtained is Su￿lent appropriate lo provide a basis for our oprLiOn. conclusitins rnlating to golng c¢)nc•m In authI￿g the finanual statements. ￿ have thal the Trustees. use of the ￿1r￿j conc8m ba$is of accounting in the prepar8tw)n ol the finarKi81 Stateme￿ is apprcyiate. Based C￿ the %wrk ￿ have performed. we have not identrf*d any malgrial unCer￿￿tIeS ftlatiro to events or conditions that, irbJNi¢knNy Ix cdlectNdy. may cast sKJrwficant doubt on Ihe Charitys abilty lo continue as a goin9 concem for a peric*J of al least ￿e4Ve mc￿thS from vthen the financial stateme￿$ are aulhorised for issue. Our responsibl1￿.eS and the respwlylilies of the Twstees *ilh reswl to goirKJ CO￿ are descfibed in the relevant Sedions of this rewt. Othw Infonnation The other Informati￿ cornprises the informab.on irKluded in the Annual rgport other than the finaneial statements and our Auditors. rep)rt th￿￿. The TNstees are respOns￿e for the other information cDntained wrthin the Annual report. Ow Opini￿ on the financial statements d[￿ r￿1 cover the other infomialion and, except lo the extent othervise expkitty stated in our report. not express any fomi of assurarKe conclusiDn thèrecffl. Our responsibilty is to read the cthr Informatic￿ and. in doing so. consider whether the other infomation is matafially inconsistent the fin￿la1 statements knovledge obtained in the course of the audit, or othe￿1$8 appears to be maten.alty misslate(J. If such material incon*sten¢ie$ or apparent material misststemenls. we are required to detemine whether this gives rise to a material misstalem8nl in the financial ststements themselves. If, basod on the work have perfom*d. 7Ae condude that there is a rna￿41 misstatement of this Oth￿ information, we are wiired to report Ihat fact. We have nothin9 to report in this fewd. Page 7 EUROPEAN ASSOCIATION FOR CANCER RESEARCH {A c¢Jmpany Ilmited by guarantee) INDEPENDENT AUDifoRS' REPORT TO THE TRUSTEES OF EUROPEAN ASSOCIATION FOR CANCER RESE*ACH (CONTINUED Matters on whkh ￿ are requlrnd to report by •xcepllon W8 have Th)Ihing to repryt n respect of ihe fC41ow￿ mallers *lwe the Charities (Accounts and Reports) Regul*iorts 2008 reqL¥res us to reF*Jt to you rf. in ow opinKffl'. the information gNon in Ihe Tntste¢s' r¢wt is in¢onwstwrt in ￿Y material respect wih the ￿na￿la1 statements., or sufficient aceountirrtj reLor(ts have not teen kw.. or the finanaal ststements are not in agreement V4ith the accounting records and retwn5'. or have not received all the infom)ation a)d expl￿atIonS we requKe fcrf our aLbJit. Responslbilltlès of trusleè# As explaned more in the Twstees. resp(Th*Jilrties statement, the Trustee$ (who are also Ihe drector5 of Ihe Chanty for the Pl*￿SeS of company law) are responsible for the prewation of the fin￿ry?1 stalemenls and for being satisfied that they give a true and f￿r and for suth intemal control as the Trustees determine is neeessary lo enoble preparation rrf fwwwl Statem￿ Ihal are free from matsrial misstatement. Vlfiether due to fraud or error. In preparing the fina￿la1 statements. ts Truslees are responsible assessing the Charitys ability to conllnue a5 a going Cor￿arn, disclwng. as appli￿￿48, mattws relaled to going concem aThJ usiTrJ the going concern basis of accounting unless Ihe Twstees either In1￿d to Ih]i*Jate the Charity or to cease operations, or have no realisbc altemative but to so. Page 8 EUROPEAN ASSOCIATION FOR CAMCER RESEARCH (A company limited by guarant••l INDEPENDENT AUDITORS. REPORT TO THE TRUSTEES OF EUROPEAN ASSOCIATK)N FOR CANCER RESEARCH {CONnNUED) Audltors. ￿pOnsIbIlItIeS f¢r th• audlt of lh• fina￿la1 statgmgnls Our ¢)bjeclives are to obtain rea$c￿e asswan¢e atrtht financial Statemènts as a whole are tree from material misstatement. whelher the lo frahj or err￿. and to issue an Auditor5. report that Indudes our opinion. ReasonatAe aSs￿￿ce is a hi&th level of asSwa￿e. but is nol a gUar￿lee that an autht conducted in accordance wilh ISAS (UK) wll aknys detect a material misstslemenl ￿en il exists Misstatements can arise from fraud or error and we Cons￿er￿￿ material rf, indrvNJually ￿ in the aggregate. they could reasonably b8 expected lo influ8nce the economic d￿S￿)n5 of users tsken on basis of these financial slalemenls. Irr8gularilies, includry fraud. are instances of rKJn-compliènce laws and wulatknns We design prc¢edwes in line with our restK)nsit)ilithes, 0uu1￿ at￿Ve. to (ktect material misstatements in reSFeCt of I￿egula￿tie$. including fraud. Th& &xtent to **¥'ch ow pyocedures are ¢apaNe of deiedty irrewlaritsas. induding fra￿fj is detailed below= Based ¢)n our understsndirvj of the company and industry. th)bfy Ihe key L3ws and regulalwjns affecting the Charity. We identified that the priwpal fisk of frthKI N nonvcomplianee with laws and regulalions related lo.. rn￿agernerrt lyas in respect of %￿UntIng estrnates I￿nts made: management overr￿9 of control.. posting of unusual journals or transa(11￿$. We focussed on those areas that could i¥ve rise to a malwial misstalement in ￿ Charitys finanaal statements. Our procedures induded. bul were not limited to" erNuiry of manag8m8nt aThJ those charged 7hryth ￿¥em￿ xtual and Wenkn'al lrtigati(Ks dwms. induding inslances of nOn<0mp￿￿￿e wth laws and regulab.ons and fraud: reviewing minLrtes of meetings of th)$e tharged wrth g0veMan￿ where available,. reviewing legal expenditure in the year to Klenlrfy inst•Kes of non.compliance wilh laws arKI regulations and fraud,. reviewng finanthal statement th'sclogjres and testing to do(xJmentslion to assass compliance with applicable laws and regulalions., performing a￿￿rt work over the risk of management overrKle of controls, induth.ng teslin9 of joumal entries other adjustments approwiatenes$. evaluab.ro the business rationale of ¥nfficanl transa¢Xions (xtside the rrfxmal course of Lwwness aTrJ reviwAiry acccmjnkng e5timate5 bias. It is the primary responsibility of Man￿eMent. with Ihe oversight of those &wged with s¥)vemancA, 10 8nsure that the enlitys operations a￿ condLKled in Wx0rd￿ *ith Ihe woviwns of laws and regulats'on$ and for thè prevention and detection of fraud. Becaus8 of the irtterent limitations of an audit. there is a iisk that we will not delect all irregularities, including those leading lo a material misstatem￿1 in the fina￿al 51atemert$ or non&compliarte V*ith regulat￿n. This risk increases the mLYe that compliance wilh a or rnwlat￿ is removed from the events transactions reflected in the financ¢al statements. as wdl be less likety to become aware of instances of non-compliance. The risk is also greater regarding l￿egUlarlkn"eS ¢>xurrmg due to fraud rather Ihan errcw, as fraud invdves In1￿11¢￿al concealment. forgery. ¢cA￿S￿. omisswm or mislewes￿1atltin. A fvrther descripts.￿ of our respon$ibilrties for the audit of the finarthql slalements is located on the Financial Reporting CoLmuI's webgte at whw.fr . This description fomis part of our Auditors, report. Page 9 EUROPEAM ASSOCIATION FOR CANCER RESEARCH IA company limited by guarantee) INDEPENDENT AUDITORS. REPORT TO THE TRUSTEES OF EUR(H>EAN ASSOCIATN)N FOR CANCER RESEARCH (CONnNUEDI Us• of our r•wt This report is m* sc4dy to the Chantys Trustees as a bth. in accordarKe wlh Part 4 of the Charities (ACC￿nIS and Rewtsl Rewlations 2008. Our audit vwxk has been wdertaken so that we might stsle lo the Charity5 Truskes those matters we are requtrred to sL*e to them in ￿ Audrtors, TepJrt and for no other purpose. To the fullest exienl permitted by kw. a¢W or assume responsibility to anyone other th￿ the Chathls and rts TTusta8s, as a body, lor audit ¥nrk. for Ihis repofL or for the opnions we have formed. PKF Smilh Coop•r Audtt Limtt•d Stslulory Audrtors 2 Lace Market Square Notty"nghom NG11PB Date.. Ils(ZoL* PKF Smith Coow A￿JIt Limited are *t4e to act as a￿j110￿5 in terms of section 1212 of the Companles Act 2006. Page 10 EUROPEAN ASSOCIATK)N FOR CANCER RESEARCH (A company Ilmlted by guarant••l STATEMENT OF FINANCIAL ACTMTIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNn FOR THE YEAR ENDED 310ECEMBER 2023 Total fund$ 2023 rot81 lunds 2022 funds 2023 funds 2023 Incom• from: Donations and kgaues Charitsble activities.. Membership income Meeting & Confe￿nCe inco Invèstsnents Other irthme 166,792 200.640 159,757 285,945 1.700,775 33.036 14.115 285.945 1,7(10,775 33,036 14,115 299.833 1.342.230 6,323 9.695 Total Incomo 2,21XI.663 2.234.S11 1,817,838 Exp8nditur• on: Rai￿ng funds Charitabla activ￿8$ 9.162 1320,908 9,162 2J54.756 14. 120 1,657,999 Total eX￿nd￿ur• 2.330,070 2,363,918 1,672, 119 Not movgmgnt In fundslnet Inc¢•m• {129A07) (129,4071 145.719 R•concilialion of funds- Tota knds brought forward la5 restated) 1.969.394 1.969.394 1,823,675 Total funds Ufrfgd forw¥d 1.839,987 1.839.987 1,969,394 The Statement of financial a¢tivities includes al gains bsses recognisad in the year. The notes on pages 14 to 31 f(¥m part ofthese statem￿. Page11 EUROPEAN ASSCCIATION FOR CAMCER RESEARCH IA cc•npany limiied by guarantrel REGISTERED 14UMBER: 07682372 BALANCE SHEET AS AT 31 DECEMBER 2023 2023 2022 T#ngible a5seis 15 SA13 7.777 Debtors due after rrK¥e than 1 y Debt￿ due bytthin 1 year Cash ai bark and tn hartd 16 16 69,981 $04,829 1249,13S 14,698 339,￿1 1389,408 1741917 Cr•dtt¢rs: one 17 (927.582) (731.839) Nel curr￿t ￿3•ts 1.896J63 ZOI2078 Total ass•tr lèss eurrent liabllltles 1.901￿76 Z019,855 Crnditor& amounts fralng after ffw)re than om ytar 18 {&1,461) Totsl ngt assets 1.839.987 1,969,394 Ch¥ity fvnds Reslrided ￿n￿$ lth￿stricted fur¥ 1.839.987 7,969,394 Totsl furtds 1.839.987 7.969.394 The Trusttts a¢kn¢)wk¢h3e Il*r respkyl8b￿tres for ccxnptyirwj the reqiirew*nts of A¢t wrth respe(* to aC4XJLmting records pr¢paralton offinanual statsrrthts. The fmanu¥l st*ements ha¥e b8an N•r*ed kn axcrfdance *ilh the wovtslorts appr￿tle to entit¢es subject to th¢ $mal g)mp*Thes regine. The ffflanaal $t*mgnts wwe approved aulIK¥is￿ the TTU8tees and spJned on tlwr ty.. Thè notès on p>3e$ 14 to 31 form pwt oflhese statwne￿. Page12 EUROPEAN ASSOCIATION FOR CANCER RESEARCH (A Company IlMFt￿ by guarant•8) STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2023 2023 2022 Cash flows fr(xn opora¢lng acllvltles Nel ¢a$h used m ¢)perating activities (Nots 22) 1171,741) 201.687 Cash flows from Investing activltl•s Proceeds frcm the sal& of tangble fixed assets p￿ChaSe of tangl￿8 fixed assets Bank interest ￿COme 490 110581 33.036 (2,941) 6,323 N•t cash provldgd by in￿￿¢1￿ aclMtI•s 31,468 3.382 Chang• in cash and cash oqulvalwls in the year Cash and cash equivalents at the begiming ofthe 11402731 2.389.408 205,069 2, 184,339 Cash and cash •4uivalMts at the end of Ihg y•ar (Note 23) 1249.135 2.389.408 rth$ on pages 14 to 31 form part ol t1￿ financial statements Page 13 EUROPEAN ASSOCIATION FOR CANCER RESEARCH (A company limited by guarantw) NOTES TO THE FINANC￿ STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 G•n•r•l Inf¢nnallon Eurorean Assouatim for Canw Re5ewth wesenls its fin￿cial statemerts lor Ihe year ended 31 Deeember 2023. The Charity is a private company limrted by ￿￿antee wKorporated in tt7e UK. The registered office address 1$ Sir CO1￿ Campbg11 BL￿d￿￿j. UniVe￿ty of fr*)ttintham IMovatv)n Park. Tri￿llPh R¢￿. Nottingham, NG7 2TU. The Charit*s regSt•Jed number is 1171827. The ChafW$ prlncipal actmty the year ¢ontinued to be that of raising funds for the a¢fvancemenl of ¢aneer research. through memberships. sponsorthps. mgetings and events. A $ummary ofthe ChariV$ accounting pc4Kies. Y4tich have be￿ ccrf*istently applied, Is set oul belw. ¢ountlng polkl 2.1 Bas1$ of pryrallon of finaKlal slat•m•nts The ffinancaal slalements teen Prep￿ in acctydance V•ith the CharitEs SORP IFRS 1021- Accounting Reporting by Chaiities." Ststement of Recommended Practiee applicable lo charities Kryaring th￿1 accounts in accordance with the F￿a￿al Reporting Standard applicabl& in the UK and ReputAK of IrelarKI IFRS 102) leffecb.ve 1 j￿Uary 20191, the Financial Reporting Standard 8ppth'(2ble •) the UK an¢J Republie of IrelaThJ IFRS 102) and the Ccrfnpanies Ad 2006. The fina￿481 SL?tem￿lS are preswtted n *rling afKI we rO￿ded to Ihe ne¥est £1. Europtsn Asscoaticrf) for C￿Cer Resewth meets the deffinit#)n of a pthlic beneffil enlity under FRS 102. Ass8ts and liabih'tias are initialty recognised at htstorical C£¢St or transaction value unless otherwise stated in th8 r818¥* ac￿l￿1ng Foh'cy. 2.2 Company ststus The Charity is a ￿MpanY Iwnited ty wantee. The memb￿5 of the Charity are the Trustees named on p￿e 1. In the event of CW beiNJ up. ts liablity in resperA of the guarantoe is mited lo £10 per member of the Charity. 2.3 Going conc•rn After m*ing aFvTcpriate 8nquiiies. lh9 trust8es have rea￿able expectatKJn that the Chartty h8$ adequate resources to ¢￿ti￿8 in OFeratKwl e￿$tenCe fof the forseeable future. Foi this reason they continue lo a(h)pt the 90ivJ corKem basks in Fry)anng thp financial Statements. 14 Fund ac¢ountin9 General lunds are unrestricied are avalable ts use at tho discrelion of the Trustees in fijrtherance of the obpc*'ves of th8 Ch)rity •KI w*¥ch have not been designated for other purpose$. Reslrided funds are fvnds **Md) are to be used in xc1)rda￿e with specifK restrictOLMs imposed by donors or which have been raised by the Charty for partIcu￿r purposes. The costs of raising and a(kninislering such ftffjds we charged against the spec4ffic fimd. Thè awn and u$e of reslriGted fund is set out in the notes to the finarK4al statements. Investment income. galns losses *e thcated to the arvrowiate ftmd. Page 14 EUROPEAN ASSOCIATION FOR CANCER RESEARCH (A company Ilmlted by guarantee) NOTES TO THE FIP4ANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 Accountlng policies (continued) 2J Incoming Resources All inwming resourcès are induded li the Statement of Financial Activities when the Charity has enlillemènl to the fvnd5. certainty of reeeyt an(J the am0￿1 can be measured with sufficient reliability. Ir￿oMe from grants are fecowise(1 Ihe Ch* has enbllemenl to the funds. any perfomiance conth"lions attached to the grants have been mel. il is probabk that the ineome be received and the omwnl ean be measured rehably and is deferred. Don*ion$ are recowised the Chanty ha5 been notified of both Ihe amount the settlement dale. In the evenl that a d(￿ation 15 $ubie¢t lo conditions that feqtwre a level of perlormance by thè ch￿rtY before the Charity is entitled to the f￿ds. the inc<>me is deferred and not recognised until either those C￿dI1￿)n$ are fi￿lY mel. or of those condth.ons is wholly wthin the control of the Chanty and It Os ryobthe thai ttr￿ Cor#it￿￿ be fumled *ittx'n the period. Meeting arKI conference irKxJme is rec>)grised 0￿8 Charity has enti11ement lo the funds. certainty of receipt aTrJ the amount ￿ be measLred wth sufficient reli*ihty - usually this is al the time of the relevant meatinglc0nfer0n￿ taking place. Membership I￿L￿ne is defeThed and recw¥sed eventy ovw the thjration ofthe membership. Other income is recwised in the perityj in *thich il 15 receivabbe to the extent the goc*Js h8¥e been provwjed ￿ on completion of the seNti. 2.6 ExpendStur• Expenditwe is ￿co￿ted for on an xcruafs basis and has been included under expense calegories that 8ggre9ale all c4)sts for to *ivitE5. w￿re costs cannot be directly attritnrted lo partiuA8r activrties. It• have been ¥kKthd (ffi a baw$ consistent Trhryth the use of resources. Costs of rasing fiJnd5 are C￿15 int)Jwed ￿ attrac1¥￿ volLm1￿ iicome. and those ineLfftd in trading ac*vities that raise fund$. Charitsble activities Governa￿e costs are costs incurred the CharTV$ wrations. including support costs and costs relalirvJ to the govern￿ of the Charity ap￿rtm)ned to charilable aclivikn'es. All costs are incurred in the putsul of Il* charitable aims of Ihe Charity. The cost base is split into direcl variatAe ￿$ts of running events. and operational overheads incurred in the ordinary course of business. Those OVerhe￿S are di5dosed in the accounts as "support costs"; these include gaIn￿OSseS ￿ f(Yeign extharvJe and noTrrecoverable VAT. The most significant element ol support cosls is the salary cost. vthich athg *Thlh certain other ¢)verheads form the fixed costs of the ¢ompany. Expenditure on charitable a¢tiwties is itwred on th"recUy undertakirvJ tha 8Ltivili8s ￿￿ch further the Chwivs objeclives, as w811 as any associated wpport ￿$ts. l ex￿dIlvre is in¢￿s1¥e of Yrecoverable VAT. 2.7 Int•r•st r•e•ivabl• Interest ￿ funds hgkl on tspowt is induded when receivable and the anounl can be measured reliably by the Charity, this is normamy w rK4iffication of the Inte￿St paid or payable by the irtstrtuth.on with wh¢xn the funds depowled. Page 15 EUROPEAN ASSOCIATION FOR CANCER RESEARCH IA Company Ilm6tod by guwantee) NOTES TO THE FINANCI￿ STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 countlng poll¢lg8 (contlnu•d> 2.8 Forolgn curronclos Monetary assets oThJ fiabilities den0mw￿ted in foreww currwKies are Ir•vslated into st8rtiThJ al rates of eXCh￿ge rLding at the reporting dale. Transaclions currew are tran￿ated wito slwlw)g at the rate rulw on the dale of Ihe transaction. Exchange gains and losses are recxrfJ￿￿ in the Statement of Financial Actbvities. 19 Taxatlon The Charty is considered lo pass the lests sol in Paragraph 1 Schedulg 6 of the Finance Act 2010 and there1￿e it meets the defini11(￿ of a Charitthe company for UK Co￿Oration lax purwses. Acc(Yth"ngly. the Cha￿ty is polenli* exempt taxalicx) in resF*d of ncome or capital gains received wrthin Categ￿e$ covwed by Chapter 3 Part 11 of the Corp)rat￿n Tax Act 2010 or Section 256 of the Taxats"on of Charge*)le Gains Act 1992. to the extent Ihat such IK(xne or gains are ap￿led exdu￿veIY to pwoses. 2.10 Tangibl• fix•d ass•ls and d•pr•ciatbon T￿Ible fix8d assets costing £1W ty more are witalisad and r8cognised ￿en future eGonom be￿fitS are probable and ￿ cost w V￿U8 of Ihe assel cw be measured reliabty. Tangible fixed assets are ￿lI1311Y recognised al cost. After recognition, mder the cost model. tsngible ffixed assets are measured at cost less aC￿Mu￿￿ted de(￿lati(￿l and any accimulated impaiment losses. All c051s incurred lo briTrJ a twgitrAe fixed asset into rts inteThJed wc*kin9 cOndit￿n Sht￿Id be ineluded wi the measLwemenl of cost. Depre￿all￿ 1$ eharged so as lo alliry basis.. Office ew1pm￿l 25% straw kne 11tD Trade aTrJ other debtors afe reeogrised at the settlemenl amount after wy trade diseount offered. Pr8payThents are valued at the am(yJrt Frybawj net of trade dTrscounts due. 2.12 Cash at bank and In hand Cash at ts￿k and in hand irKludes cash slKXt-temi highly liwid inveslmenls v￿h a short maturity of three months or less from Ihe date of wuisitscffi or opening of deposit or similar accounL Page 16 EUROPE*A ASSOCIATION FOR CPJ4CER RESEARCH (A company limit•d by guarant•el NOTES TO THE FINANCIAL STATEMENTS FOR THE YE*R ENDED 31 DECEMBER 2023 Accounting polkl•s l¢ontlnued) 2.13 Llabllitlos and byovlslons Liabilib"ès arè recognised the￿ is an obligaiKin at Ihe Balan￿ sheet d*e as a result of a past event, il is probable that a transfer of e¢c¢￿•C benefit %%ill be required in settlem8nl. and the amount of the selUem8nl can be eslThaied relia￿. Liabilities are recognised at tho amount that the Chanty anticipates il wll pay lo settle Ihe debt or the •mounl il has r￿1ved as adva￿e￿ pas•n￿ts the 9)ods or services il must provide. Provisions we n￿aSU￿ atthe best estimate ofthe amcths reqirnl to settl8 th8 obligati(Jn. 114 Flnanclal Inslrum•nts The Charity (#* has financial assets WKI fvw￿l li*>ililie5 of a kind that qualify as basic financial instruments. Basic financial instrunwnls are iThtially recognised at transaction value and subsequently measured at thLwr settlement value with Ihe ?xc8PtK￿ of bank h)ans whieh are subsequendy measured at amortised cost ￿r￿j effeL#ive interest method. 2.15 Owrating lea￿3 Rent￿S paid under ￿Tating leases we ¢h¥ged to the Statement of Financial Activities on a slrtight-￿ne basis o¥w the lease twm. 2.16 P•nsitins The Charity cperate5 a defv*d c￿ntr11X1t￿ pensh)n scheme the pension chargè repres6nts the ncunls payable by the Chwty io Ihe furKI in respect of the sear. Crhlcal accounting ¥stimat￿ and ar￿* of judgm•nt In ts ap1A￿atiOn of the Charitys accowting policies. vthich are desuibed in No18 2. management is required lo make judgements, osts"male5 aTrJ assumpts.ons about the carryng value of assets and liabilrtie$ that a￿ not readily apparenl from oltr￿r sour¢e$. The e$timates and undedwng assumpthons are based on historical experien￿ otsr factors thai are considared to be relevant. Actual results may drffer from these estimates. The estimates and Ur￿￿1)g assumptw)ns a￿ mith¥ed on an cffwing basis. Revision5 to accounting estimales are recowised in the p￿10d irb the estimate is revised if the reviSic￿ affed$ only that period. or in the period of rwision and fuiure yio(ts if afferts both c1jr￿1 fulure years. The Trustees have Th)t identified eny critK* or k8y Sour￿ of estimation uncertainty in prepamg these financial ststemenls. Page17 EUROPEAN ASSOCIATION FOR CANCER RESEARCH (A ¢¢>npany lin￿ by guarants•l NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAJi ENOED 31 DECEMBER 2023 Incom• from donatlons and Wl•s R•strlcted Unrestrlcled funds lunds 2023 2023 Total funds 2023 Donat*)ns Grants 4,690 162,102 4.690 195.950 33.848 33,848 166,792 200,640 Re￿iCted Unrestiicted fvnds lunds 2022 2022 Tolal funds 2022 DOna￿e￿$ Grants 17.344 137.248 17,344 142,413 5. 165 5.165 154.592 159, 757 Incomo from ¢harll*>k actlvltlos Unr•stricted fvnds 2023 Total funds 2023 Memberslip income Meeting and conference inccrfna 285,945 1,700.775 285.945 1,700.775 1.986.720 1,986.720 Unr8sliict8d funds 2022 Tolal funds 2022 Memberstw'p irthme Meeting and Confere￿ i￿ome 299.833 1.342,230 299,833 1.342.230 7,642,063 1,642,063 Page 18 EUROPEAN ASSOCIATION FOR CANCER RESEARCH A company limit•d by guarant••) NOTES TO THE FIPIANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEIABER 2023 Inveslm•nt In¢om• Unrestricted funds 2023 Total funds 2023 B￿k interest received 33,036 33.036 Unrestiicted fvnds 2022 Total funds 2022 Bank interest rtteived 6,323 6,323 Page19 EUROPEAN ASSOCIATION FOR CANCER RESEARCH (A company limited by guaranle•l NOTES TO THE FINANCI*L STATEMENTS FQR THE YEAR ENDED 31 DECEMBER 2023 Other In¢omlng ￿¢)￿￿09 Unrestrl¢t•d Total funds 2023 2023 0￿r inccYnirwJ resources 14,115 14.115 Unrestric(e)sts 5.165 1.652,834 1.657.999 10. Anatysis of expendiiurn by actlvltles Adlvlti•5 und•rtak•n directty 2023 Support cosls 2023 Total fvnds 2023 Charitsble *iwty 1,546,210 808,546 2.354.756 Page21 EUROPEAN PS￿ClAT1oN FOR CANCER RESEARCH IA Company Ilmit•d by guaranleel NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 1D. jmatysls ol •xp•nd6turn by a¢llvltl•s (¢ontlnu•dl Actiwlies Support cosls Tolal funds 2022 dff8cUy 2022 2022 Charilatle xtivity 964,576 693.423 1.65T.999 Anatysls of supwt co Total fuTrd¥ 2023 Total funds 2022 605,234 4.321 39.518 625 503.464 3,927 39.401 4. 701 159 6,468 4,926 16,577 Depredation Rent (operating leases) Office costs Te￿phOne COmp￿er costs Stsff training Travelling expenses and enterta1rn￿t Profit on disposal of fixed assets Legal and professional Bad debts Insuran Bank tharges Sundry expen Loss I Iproffitl ￿ forew ex¢harvJe FOre￿n taxes 8.169 8.053 13.387 (490) 76.142 56.213 3.318 13,364 12,239 4.220 7,983 (1,814) 18,2TT 15,780 11,469 3.211 (6,130) 23,369 808,546 693,423 lnC￿jded wthin govemance costs 15 £9.07S (2022.. £7.500) in respect of aLbJitorfs remunerati￿, £1,815 (2022.. £1.$00} in respect of audito¢s non audit ¢osts and È11.72912022'. £9.277) in respect of Trustee expenses and other expenses in relati￿ lo attendance at board meetings.. Page 22 EUROPEAN ASSOCIATION FOR CANCER RESEARCH (A company Ilmltod by guarante•} NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 11. Audltors. r•muneratlon 2023 2022 Fees payatAe to the Ch*515 althor the awjt Ch￿9 annual accounts 9.075 7,500 Fees payable to the Chartys aKltor in iespec* of. I non-audit services not indL*J￿1 atrAwe 1,815 7,500 11 Staff costs 2023 2022 Wages salaries s￿la1 se¢urtty eosts Contribution to defined contrtjulion rension sc**mes 496.322 41.509 67,403 411.461 37.787 54.216 605234 503,464 The average number of persons employed bythe ch￿ dLwing the Jear was as follows.. 2023 2022 Employeès 15 14 The number of emFAosws kne emploype benefrts (exduding employer pension ¢o$t$) exceeded £60.000 was: 2023 No. 2022 In the barKI £70,001- £80,000 In the baTrJ £80.001 - £90,000 Key management pe1X￿n￿ irtludes those pers￿ ththo ar8 inthded on the administratfve page. The key management employee benefft5 linduding employer pension contributions arKI efflpk1￿r national insurance contriiwticfflsl for the year toialed £109.666 (2022.. £104.4361 Page 23 EUROPEAN ASSOCIATION FOR CANCER RESEARCH IA company Ilmited by guarantw) NOTES TO THE FINANCI￿ STATEMENTS FOR THE YEAR ENDED 310ECEM8ER 2023 13. Trustms. r•munoratlon and •xp•ns Duthg the year. no Trustees rec*ved any r￿￿j￿￿tiOn or cther benefits (2022. £NILJ. Lhjriig the year ended 31 Decemter 2023. gxpen¥es t￿aIng £4.514 ware rewnbur$8d or paid diredly to to 13 TTUStees {2022- £4.796 ro I l Tn￿$). l expenses relate dIr￿lY to Ihe att8Th1￿ al wb'r¥Js. 14. Actlng as an Agent During the year. the EuroFean Asso¢lat￿ fy Caw Research acied as an agent on behalf of olher enlilies. The chanty has acted in accordm to with Section 19 of Ihe Chwrties SORP and no knnds are recognised as an asset at year end. Within tho year, th8 Charty received inccffle of £103.373 and passed on £76,745. Al the feportiig dale. the net posiliton of funds ￿k1 is a creilit to the baiarKe sheet of £26.025. This is included wthin other cr9di1￿ as al the ypar WKI. 15. Tangiljle fix•d asséts Offlc• quipm•nl Cost or valuatlon At 1 January 2023 Addrtions Disposals 21.886 2.058 (1.569) At 310ecember 2023 22.375 D•prg¢latlon Al 1 January 2023 Charge for the Jtar On disposals 14109 4,322 (1.5691 At 31 December 2023 16,862 N•t book valu• At 31 Decembér 2023 5,513 A¢ 31 December 2022 7,777 Page 24 EUROPEAN ￿SsocIATION FOR CANCER RESEARCH IA company limited by guarantsel P40TES TO THE FINANCI￿ STATEMENTS FOR YEAR ENDED 31 DECEMBER 2023 l& D•btors 2023 2022 rkn after more than one year Prepayments and acwed inLyJ Due wlthln one year Trade debtors Other debtors Prepaynents arwj ac¢ru¢d Ir￿n• 69.981 14,698 161.148 21.065 322.616 192,772 1,718 145.321 $74.810 354,509 17. Creditors: Amounts lalllng due wlthln one year 2023 2022 Trade ueJs 659.990 586,270 825,569 583,058 (593.6311 (509.332) 891.934 659,996 Defeffed irKome as at 31 t)e￿ber 2023 is split as £830.046 {2022. £609,535) du8 < 1 year and £61.889 (£50,461) due > 1 year. Deferrèd Irthme as at 31 Decemkr 2023 relates to: - £120k of membership In￿ne Trn advance (2022: £98k) - £711 k of registralKJn aTrJ sponsorship in a¢*ance (2022: £514kl - £61k of grants in advanc&12022: £48k) Page 26 EUROPEAN ASSOCIATION FOR CANCER RESEARCH (A company limit￿ ty guarant••) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 20. Stst•mènl ol fvnd$ Stat•m•nt ol funds . curr•nt y•ar Balance at 31 D0￿Mb•r 2023 Balanco at 1 jarn￿ry 21n3 Incom Expendliurn UnT•strfcted funds General Funds 1.969.394 2,200.663 (2.330.070) 1.839,987 Rttstrict¢d funds Restricled Fund 33,848 (33.8481 Total of lunds 1.W.394 2,234511 {1363.918> 1.839.987 Page 27 EUROPE￿ ASSOCIATION FOR CANCER RESEARCH (A company Ilmltod by guarantoel NOTES TO THE FINANCIAL STATEMEMTS FOR THE YEAR ENDED 31 DECEMBER 2023 20. Statement of fvnds l¢ontlnu•d Statement of funds. wlor year Balancg al 31 December 2022 l January 2022 Income Expenditure Unrnstrlctod fund$ Gerwal Funds 1.823.675 1.812.673 (1.666,954) 1.969,394 R•*trkt•d fvnd* Restricted FurKls- all fwwJs 5. 165 (5, 165) Totsl of funds 1.823,675 1,877.838 (1,672, It9J 1,969,394 Reserves are ￿reStrIcted fuvmls ¥*tMch are availabl8 for use at the discT8tson of tho Trustees in furtherance of the weral Obje￿yeS of the Charily and tfftthich h￿e not been designated for other Restncted fijnds *e funds wthich are to be used in alxordance With specffic restrictions imp)sed by donors or have bean raised by the CW for partKLdar purposes. 21. Summary ol fund• Summary ol funds- ¢Ufr¢nt y Balance at 31 D•cember 2023 Balanc9 at 1 JaNary 2023 Incom• Expenditure General I￿lJ5 Restricted frjnds 1,W.394 23IXI.fj63 12,330.0701 1,839,987 33,a48 (33,8481 1.969.394 2.234.511 12.363.918} 1.839.987 Page 28 EUROPEAN ASSOCIATION FOR CANCER RESEARCH (A company limitod by guarant•81 NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 21. Sumrn•ry of funds (continu￿> Summary ol funds- Fxior y•* Balance al 31 December 2022 Balance at l January 2022 Income Exp8ndkure General funds Restricted funds 1.823.675 1.812.673 (1.666,954) 5.165 (5. 165) 1.969,394 1.823.675 1.817.838 (1.672. 119) 1,969.394 Analysls of n•t assets bolwwn funds Analysls of Thgt aS$9ts ￿lWoo￿ lunds. currenl y••r Unr•strict•d nds 2023 Total funds 2023 TangiNe fixe(l assels Debtors due after more th￿ one year Current assets Creditors within s)ne year Cr¢ditcts dué in morn Ihan one Jear 5,513 69.981 2,779.989 1953.607) (61.889) 5,513 69,981 2.779.989 (953.6071 {61.8891 Total 1,839,987 1,839,987 Anatysis of net ass•l$ b•tw•on fund$ . prl¢v y￿r UftTrstrKled funds Total Funds 2022 2022 Tangible fixed assets Debtois due after more Ihan ￿e y Current assets Creditors due ￿thIn one Creditors thJe in more Ihan ￿ >ear 7,777 14.698 2.729.219 (731,839) (50,461) 7. 777 74,698 2,729,219 1731.839) (50.461) Total 1.969.394 1,969,394 Pag8 29 EUROPEAN ASSOCIATION FOR CANCER RESEARCH (A company liMh￿ by gu¥ants• NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 310ECEM8ER 2023 23. R¢¢0￿111811on of n•t mov•m•nt In funds to n•t cash flow from opwatlng aetl¥iti•s 2023 2022 Net incomeleypenthture lor the {as per Statema* of Fw*ncial Activities) 1129.407> 145, 719 ustments for: tkpreuatson charges {Pr¢)fft} cffi the sale of fixed assets Increase in debtors Increase in credilors Investmerrt income 4,321 14901 1220.3001 207.171 133.036) 3,927 (6,064) 64.428 (6,323) Nèt cash provld•d byl(us•d Sn) operatlng a¢ttvltl•s 1171.741) 201.687 24. Analysls of cash and •quival•rbts 2023 2022 Cash In haTr 2.249.135 2.389.408 25. Analysls of changes In not dobt At31 0ocemb•r 2023 January 2023 Caih flo Cash at b￿k arKI in h￿d 2.389,408 1140.2731 2,249.135 2.389.408 {140.2731 2.249.135 26. P•nslan commlthi•nts The Chorty wrales a dofined ¢￿tributiOn sdvne Tr assets of the stheme are held separately Irom those of the Charity in an irthpgndentty administered fvnd. The pension cost chafgg represents contributions payable by the Chwity to the fund and amounted to £67.403 (2022 £54,216> Contribulion5 lot￿*"ng ENIL12022.. £12.0931 V•we payabse lo the lund at the balance sheet dale are induded in crethiors. Page 30 EUROPEAN ASSOCIATION FOR CANCER RESEARCH IA company 11m1t￿ by guarant•• NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 27. Operating lea￿ ¢¢)mmltm•nts At 31 December 2023 the Charity had cwimitynents ￿ make fuiure minim￿￿ lease pa￿nentS uThJ8r non ancelable ¢)perating leases as follows.. 2023 2022 Not later than 1 year 25,486 24,247 Page 31